International
A drug used for diabetes, which works in a similar way to Ozempic, has shown some promise in a clinical trial for early-stage Parkinson's disease. The drug, lixisenatide, is a glucagon-like peptide-1 receptor agonist and compared to placebo it has been found to help slow the progression of motor disability after 12 months in a small phase 2 trial. The researchers also found significant gastrointestinal side effects including nausea in 46% of people receiving lixisenatide, and vomiting in 13%. They say longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson’s disease.
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
